Kythera Plans $100 Million Stock SaleLos Angeles Business JournalKythera Biopharmaceuticals Inc. announced on Monday a $100 million secondary stock offering as it prepares to seek FDA approval of its groundbreaking drug that reduces double chins. The Calabasas biotech, which went public last October, is seeking to ...and more »
This post is a mere snippet of world-wide industry news, sponsored by:
BizLocal is a web-property of Inspetta LLC, providing innovative web, software and marketing services to business. Call 800-785-2925 for more information.